I'm a liver specialist treating HCV patients over past 10 years...

I'm a liver specialist treating HCV patients over past 10 years and also in clinical trials - I don't rely on my local chemist for information about HCV medications. The major issue for BIT225 in HCV is that it's just not very effective when measured against medications the 5 major companies already have in trial or on the market. The HCV pie is now rapidly shrinking in the first world (e.g. France expects eradication by around 2020) and given the length of time it takes to get a new drug to market that pie will be very small indeed for anyone still in early stage trials if they were ever get to market. On that background I cannot see a reason why anyone would now be interested in BIT225 as an HCV treatment.

How much skin in the game the directors have is important information, as if they are on good salaries without significant equity interest then there's little incentive to make hard decisions in a timely fashion. As it stands I can't see how a company this size that is most definitely not expanding can justify a directorship of its size.